top of page

PrIMAVeRa project partners present posters at ECCMID 2024

29-30 April 2024


Members of the PrIMAVeRa team shared challenges & solutions for data-sharing & re-use, and expert consensus on priorities for vaccine/mAb R&D and implementation on 29&30 April at ECCMID 2024 in Barcelona.


Members of the PrIMAVeRa team at ECCMID 2024

Mariana Guedes shared challenges encountered through the course of project activities regarding data-sharing and re-use in research, and corresponding solutions, while Nasreen Hassoun-Kheir shared the results of expert elicitation on AMR research priorities for development and implementation of #vaccines and #mAbs.  


Multiple conference participants discussed the potential applications of vaccines and monoclonal antibodies in tackling AMR. There was a lot of interest in PrIMAVeRa, not only regarding its innovative approach of leveraging vaccines and monoclonal antibodies against AMR but also regarding the project design, partners and anticipated outcomes. Attendees also showed keen interest in the research agenda, particularly in prioritizing certain pathogen-infection combinations and not others for future research. The expert elicitation methods, considerations and major results were also explained. 


Attendees that visited the poster presentation were very interested in the process implemented by Work Package 3 to gather individual patient level data to inform mathematical models to estimate the impact of vaccines and mAbs on AMR. Conference participants had similar challenges in their projects and exchange experience within the scientific community in gathering data for secondary use was rewarding. PrIMAVeRa partners were praised for their work and achievements.


 Keep up to date on project developments here:


This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the author's view, and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.


Commenting has been turned off.
bottom of page